MD Primer Inc. Advises that it Intends to Acquire Approximately Two Million Shares in CardioComm Solutions from the Free Trading Pool on the Open Market.
Toronto, Canada - CardioComm Solutions, Inc. ( TSX-V:EKG) ("CardioComm Solutions" or the "Company"), a global medical provider of ECG acquisition and management software solutions, is pleased to announce its major shareholder, MD Primer Inc . ("MD Primer") has confirmed their intent to purchase additional shares of CardioComm Solutions on the open market on a monthly basis.
MD Primer is the largest shareholder of CardioComm Solutions and has advised CardioComm Solutions that it plans to increase its total holdings of the Company by approximately two percent (2%) through purchases of shares on the open market. MD Primer is under the control and direction of Dr. Anatoly Langer, CardioComm Solutions' Chairman. MD Primer Inc. is a Canadian company with North American expertise in the design and conduct of clinical trials, patient registries, practice enhancement programs for physicians, and the development and execution of accredited medical education events as well as assuming a growing expertise in electronic medical records systems.
"I am pleased with the direction of the Company. For CardioComm Solutions, 2012 was a year of heavy R&D investment and product preparation and 2013 will represent the year of market access for its products and services. I believe that the current share price does not reflect the company's pipe line of products or its true value," said Dr. Anatoly Langer, President of MD Primer Inc.
MD Primer has previously provided the Company support through the introduction of equity financing and access to preferred rates for lines of credit. "The access to funding from MD Primer has permitted CardioComm Solutions to move forward in the achievement of significant intellectual property gains especially in the past three years. We have been able to effectively pursue multiple product and software clearances without fear of external lender pressure. Now, with the only consumer-ready, over-the-counter ECG enabled heart rhythm monitor cleared for sale in North America and the December 2012 CE mark approval to open European Union sales and marketing efforts, we can focus on revenue generation," said Etienne Grima, CEO of the Company.
About CardioComm Solutions
CardioComm Solution's patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms (ECGs) for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. The company has earned the ISO 13485 certification, is HPB approved, HIPAA compliant, and has received FDA market clearance for its software devices. CardioComm Solutions, Inc. is headquartered in Toronto, Canada, with offices in Victoria, B.C.
FOR FURTHER INFORMATION ON CARDIOCOMM SOLUTIONS PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
This release may contain certain forward-looking statements with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release
Leave a comment...